Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Time: 12:00 –
Session Title: 12e. Drug development and treatment modalities (including in vitro, animal, clinical trials, resistance)
Poster Number: P2633
Title: “EDP-235, a Potent,
Time: 12:00 –
Session Title: 1c. Influenza and respiratory viruses (including diagnostics and epidemiology, antiviral drugs, vaccines, treatment and susceptibility/resistance)
Poster Number: P2844
Title: “Pharmacokinetics of EDP-323, a Potent,
Posters will be available to view on the conference platform during the conference. Further information about ECCMID 2023 can be found here.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
Media and Investors